Insight Molecular Diagnostics vs Renovorx
Insight Molecular Diagnostics is the larger business, with $4.1m of revenue in fiscal 2025 against $1.1m for Renovorx (3.6 times as much). Renovorx grew faster (2511.6% against 115.6%). Renovorx kept more of each dollar of sales as profit: a net margin of -994.5% against -1238.5%.
| Latest fiscal year | Insight Molecular DiagnosticsIMDX, 2025 | RenovorxRNXT, 2025 |
|---|---|---|
| Revenue | $4.1m | $1.1m |
| Revenue growth | 115.6% | 2511.6% |
| Net income | −$50.2m | −$11.2m |
| Operating margin | — | — |
| Net margin | -1238.5% | -994.5% |
| Return on equity | — | — |
| Free cash flow | −$25.4m | −$11.0m |
| Cash | $11.6m | $7.0m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 17 |
| Market value | $91.3m | $57.8m |
| Price vs our value range | — | — |
| Moat score | 20 (Weak) | — |
| Insider trades, 12 months | 14 buys, 0 sales | 13 buys, 0 sales |